托维妥单抗

托维妥单抗
单克隆抗体
种类?
目標PDGFRA
臨床資料
ATC碼
  • 未分配
识别信息
CAS号1243266-04-7
ChemSpider
  • none
UNII
KEGG
化学信息
化学式C6400H9906N1726O2002S54
摩尔质量144,792.97 g·mol−1

托维妥单抗（INN：Tovetumab）是一种抗PDGFRA单克隆抗体，设计用于治疗癌症。[1]它由MedImmune开发，并试验用于胶质母细胞瘤和非小细胞肺癌。[2]对于该药物的开发于2013年停止。[3][4]

存卡里

[编辑]
  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Tovetumab, American Medical Association.
  2. ^ Liang M, Wang B, Schneider A, Vainshtein I, Roskos L. A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy. The AAPS Journal. November 2020, 23 (1): 4. PMID 33210183. S2CID 227067803. doi:10.1208/s12248-020-00523-3 可免费查阅. 
  3. ^ Tovetumab. AdisInsight. Springer Nature Switzerland AG. [2024-03-01]. （原始内容存档于2017-11-03）. 
  4. ^ Williams R. Discontinued in 2013: oncology drugs. Expert Opinion on Investigational Drugs. January 2015, 24 (1): 95–110. PMID 25315907. S2CID 23390614. doi:10.1517/13543784.2015.971154.